[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:undifferentiated-pleomorphic-sarcoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":66,"states":67},"Undifferentiated Pleomorphic Sarcoma",9,[7,15,22,29,35,42,48,54,60],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05607095","A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma",[11],"Phase 1","RECRUITING","2026-08-26T02:18:51.009190Z","2026-07-19T19:36:05.123927Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06422806","Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas",[19],"Phase 3","2026-08-26T02:16:23.080181Z","2026-05-05T02:43:27.931275Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT07283731","Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced\u002FMetastatic Soft-tissue Sarcoma",[26],"Phase 2","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:27.740604Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT04332874","A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg",[26],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:27.645373Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":40,"content_modified":41},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[39],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":43,"title":44,"phases":45,"status":12,"updated_at":46,"content_modified":47},"NCT05711615","Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma",[11],"2026-08-26T02:19:30.857183Z","2026-07-05T05:32:16.811405Z",{"nct_id":49,"title":50,"phases":51,"status":12,"updated_at":52,"content_modified":53},"NCT06789172","A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",[11],"2026-08-26T02:16:18.872924Z","2026-07-05T05:32:16.698119Z",{"nct_id":55,"title":56,"phases":57,"status":12,"updated_at":58,"content_modified":59},"NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas",[26],"2026-08-26T02:15:37.042762Z","2026-05-05T02:43:27.251035Z",{"nct_id":61,"title":62,"phases":63,"status":12,"updated_at":64,"content_modified":65},"NCT06113809","Palbociclib and Pembrolizumab in Sarcoma",[11],"2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.898243Z",[],[68,72,76,79,82,85],{"state":69,"count":70,"slug":71},"Texas",4,"texas",{"state":73,"count":74,"slug":75},"California",3,"california",{"state":77,"count":74,"slug":78},"Illinois","illinois",{"state":80,"count":74,"slug":81},"Massachusetts","massachusetts",{"state":83,"count":74,"slug":84},"Missouri","missouri",{"state":86,"count":74,"slug":87},"New York","new-york"]